Acumen Pharmaceuticals Files 8-K on Shareholder Vote
Ticker: ABOS · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1576885
| Field | Detail |
|---|---|
| Company | Acumen Pharmaceuticals, INC. (ABOS) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Acumen Pharma had a shareholder vote on 6/4, details to follow.
AI Summary
Acumen Pharmaceuticals, Inc. filed an 8-K on June 5, 2025, reporting on matters submitted to a vote of its security holders on June 4, 2025. The filing does not disclose the specific details of the vote or the matters voted upon.
Why It Matters
This filing indicates a shareholder vote occurred, which could signal significant corporate actions or decisions impacting the company's direction and shareholder value.
Risk Assessment
Risk Level: medium — The filing is a standard 8-K for a shareholder vote, but the lack of specific details about the vote's outcome or subject matter introduces uncertainty.
Key Numbers
- 001-40551 — SEC File Number (Identifies the company's filing with the SEC.)
- 36-4108129 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Acumen Pharmaceuticals, Inc. (company) — Registrant
- June 4, 2025 (date) — Date of earliest event reported
- June 5, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Newton, Massachusetts (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Acumen Pharmaceuticals, Inc. security holders on June 4, 2025?
The filing does not specify the exact matters voted upon, only that a submission to a vote of security holders occurred.
What was the outcome of the shareholder vote on June 4, 2025?
The filing does not disclose the results or outcome of the shareholder vote.
When was this 8-K report filed with the SEC?
The report was filed on June 5, 2025.
What is the principal business address of Acumen Pharmaceuticals, Inc.?
The principal executive offices are located at 1210-1220 Washington Street, Suite 210, Newton, Massachusetts 02465.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Acumen Pharmaceuticals, Inc. (ABOS).